Purified Protein Derivative Induced Cytotoxicity in Carcinomatous and Tuberculous Pleurisy

Japanese Journal of Medicine

Volumn 27, Issue 3, 1988, Pages 255-260

  Okubo, Yoshio ^a   Namushi, Namushi R ^b   Nakata, Masao ^b   Kuroiwa, Yasushi ^b   Ota, Teruo ^b   Kusama, Shozo ^b  

^a SHINSHU UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinomatous pleurisy; Cytotoxicity; Purified protein derivative; Tuberculous pleurisy

Indexed keywords

INTERFERON; INTERLEUKIN 2; TUBERCULIN;

CARCINOMATOUS PLEURISY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PLEURISY; TUBERCULOUS PLEURISY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CELL LINE, TRANSFORMED; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMAN; INTERFERONS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGE; PLEURAL EFFUSION; RESPIRATORY TRACT NEOPLASMS; TUBERCULIN; TUBERCULOSIS, PLEURAL;

EID: 0023706874     PISSN: 00215120     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine1962.27.255     Document Type: Article

References (16)

1. Herberman R. B., Hoden H. H.,: Natural cell mediated immunity. Adv Cancer Res 27: 305, 1978.
2. Dobloug J. H., Forre O., Kvien T. K., et al: Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Ann Rheum Dis 41: 490, 1982.
3. Okubo Y., Nakata M., Kuroiwa Y., et al: Phenotypic and functional study of natural killer cells in tuberculous pleurisy patients. Jpn J Med 25: 250, 1986.
4. Agostini C., Trentin L., Zambello R., et al: Phenotypical and functional analysis of natural killer cells in sarcoidosis. Clin Immunol Immunopathol 37: 262, 1985.
5. Baley J. E., Schacter B. Z.,: Mechanisms of diminished natural killer cell activity in pregnant women and neonates. J Immunol 134: 3042, 1985.
6. Semenzato G., Agostini C., Zambello R., et al: Lung T cells in hypersensitivity pneumonitis: phenotypic and functional analyses. J Immunol 137: 1164, 1986.
7. Okubo Y., Nakata M., Kuroiwa Y., et al: NK cells in carcinomatous and tuberculous pleurisy. Phenotypic and functional analyses of NK cells in peripheral blood and pleural effusions. Chest 92: 500, 1987.
8. Kohase M., Kohno S., Yamazaki S., et al: The clinical potential of interferons: Potency standardization of human interferon preparation for clinical trials. p 299, University of Tokyo Press, 1980.
9. Wolfe S. A., Tracey D. E., Henney C. S.,: Induction of “natural killer” cells by BCG. Nature 262: 584, 1976.
10. Wiltrout R. H., Mathieson B. J., Talmadge J. E., et al: Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J Exp Med 160: 1431, 1984.
11. Kalland T., Aim G., Stalhandske T.,: Augmentation of mouse natural killer cell activity by 2616, a new immunomodulator. J Immunol 134: 3956, 1985.
12. Salata R. A., Kleinhenz M. E., Schacter B. Z., et al: Augmentation of natural killer cell activity by lipopolysaccharide through separable effects on the binding of non adherent lymphocytes to tumor target and tumor killing. Cancer Res 44: 1044, 1984.
13. Storkus W. J., Howell D. N., Salter R. D., et al: NK susceptibility varies inversely with target cell class 1 HLA antigen expression. J Immunol 138: 1657, 1987.
14. Henney C. S., Kuribayashi K., Kern D. E., et al: Interleukin-2 augments natural killer cell activity. Nature 291: 335, 1981.
15. Bloom E. T., Babbitt J. T., Kawakami K.,: Monocyte-mediated augmentation of human natural killer cell activity: conditions, monocyte and effector cell characteristics. J Immunol 137: 172, 1986.
16. Uchida A., Micksche M.,: Suppressor cells for natural killer activity in carcinomatous pleural effusions of cancer patients. Cancer Immunol Immunother 11: 255, 1981.